REQUEST
A REP

Durable PASI response rates through ~3 years1*

LTE post-hoc sub-analysis

PASI response rates with continuous SOTYKTU treatment in patients entering PSO-LTE

Data is from PSO-LTE: pooled PSO-1 and PSO-2 through Week 148 (mNRI)1

LTE LIMITATION: In open-label LTEs, patients who lose response or are unable to tolerate treatment are likely to discontinue treatment, which may raise the proportion of responders in the overall population.

  • Data are derived from post-hoc sub-analysis of PSO-LTE and includes only patients from PSO-1 and PSO-2 who received continuous SOTYKTU from Day 1 (Week 0) and entered the LTE (n=513, entered; n=456, mNRI). Outcomes were analyzed descriptively1
  • Note that the SOTYKTU arm of PSO-2 had forced re-randomization of half of the PASI 75 responders at Week 24; these patients are not included in this analysis, as they were no longer under continuous treatment1,2
  • Data cutoff was at 148 weeks.1
  • LTE=long-term extension; mNRI=modified non-responder imputation; PASI=Psoriasis Area and Severity Index; PASI 75=≥75% reduction from baseline in PASI score; PASI 90=≥90% reduction in baseline PASI score.

Are you ready to explore more? Select a topic below.

References:

  1. Armstrong AW, Lebwohl M, Warren RB, et al. Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials. Oral presentation at: European Academy of Dermatology & Venereology (EADV) Congress; October 11-14, 2023; Berlin, Germany.
  2. Warren RB, Sofen H, Imafuku S, et al. Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. Poster presented at: European Academy of Dermatology & Venereology (EADV) Spring Symposium; May 12-14, 2022; Ljubljana, Slovenia. Poster P465.
  3. ClinicalTrials.gov. NCT04036435. https://clinicaltrials.gov/ct2/show/NCT04036435. Accessed June 8, 2023.

Back to top